

SKYEPHARMA PLC  
Form 6-K  
May 15, 2007

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of May, 2007

SkyePharma PLC

---

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

---

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

---

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

### SkyePharma PLC - Annual Information Update

In accordance with the requirements of Prospectus Rule 5.2, the following summarises the information and documents published, or made available to the public, by the Company between 3 May 2006 and 14 May 2007 inclusive. The information referred to in this update was up to date at the time it was published but some information may now be out of date.

#### 1. Announcements via RNS

The following UK regulatory announcements have been made via RNS a Regulatory Information Service and can be obtained from the London Stock Exchange website at [www.londonstockexchange.com](http://www.londonstockexchange.com) or the Company's website at [www.skyepharma.com](http://www.skyepharma.com)

<u>Date</u>	<u>Announcement</u>
3 May 2006	Share Purchase Plan
8 May 2006	Flutiform Deal
8 May 2006	Conference Call Details
17 May 2006	Board Appointment
19 May 2006	Director Declaration
22 May 2006	First Horizon Deal
31 May 2006	Asco Presentation
31 May 2006	Share Purchase Plan
12 Jun 2006	Re Convertible Bonds
15 Jun 2006	Notification of Shares
21 Jun 2006	Business Review
28 Jun 2006	AGM Statement
30 Jun 2006	Re: DepoBupivacaine Rights
4 Jul 2006	Share Purchase Plan
10 Jul 2006	Notification of Shares
28 Jul 2006	NASDAQ for Compliance
1 Aug 2006	FDA Filing
1 Aug 2006	Share Purchase Plan
4 Aug 2006	Notification of Shares
8 Aug 2006	Adviser Update
11 Aug 2006	Re: Share Price Movement
21 Aug 2006	Appointment of Auditor
31 Aug 2006	Share Purchase Plan
5 Sep 2006	Notice of Results
6 Sep 2006	European Flutiform Deal
22 Sep 2006	Personnel Changes
28 Sep 2006	Interim Results
4 Oct 2006	Positive Data & EU Filing
4 Oct 2006	Director Shareholding
9 Oct 2006	Company Secretary Appointment
20 Oct 2006	Notification of Interest
24 Oct 2006	NDA for Zileuton CR
25 Oct 2006	Notification of Shares
27 Oct 2006	Notification of Shares
31 Oct 2006	Conference Presentation
2 Nov 2006	Share Purchase Plan
7 Nov 2006	Positive Flutiform Update
14 Nov 2006	Board Appointment
20 Nov 2006	Presentation at Conference
22 Nov 2006	Notification of Interests
24 Nov 2006	Notification of Interests
27 Nov 2006	Notification of Shares
28 Nov 2006	Solaraze Approval
30 Nov 2006	Share Purchase Plan
18 Dec 2006	FDA Approves Certihaler

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

18 Dec 2006	Transparency Directive
19 Dec 2006	Major Interest in Shares
27 Dec 2006	GBP35million Fundraising
28 Dec 2006	Notification of Shares
3 Jan 2007	Share Purchase Plan
4 Jan 2007	Notification of Shares
9 Jan 2007	Injectable Sale & Placing
9 Jan 2007	UK Release Important Details
16 Jan 2007	Circular Posting
22 Jan 2007	Notification of Shares
29 Jan 2007	Notification of Interests
1 Feb 2007	Share Purchase Plan
8 Feb 2007	EGM Statement
14 Feb 2007	Presentation at Conference
20 Feb 2007	Notification of Shares
1 Mar 2007	Share Purchase Plan
9 Mar 2007	Presentation at Conference
12 Mar 2007	Holding(s) in Company
13 Mar 2007	Holding(s) in Company
15 Mar 2007	Agreement for Zileuton CR
26 Mar 2007	Completion of Disposal
26 Mar 2007	Total Voting Rights
2 Apr 2007	Interest in Shares
2 Apr 2007	Interest in Shares
3 Apr 2007	Annual Information Update
3 Apr 2007	Interest in Shares
3 Apr 2007	Director Shareholding
13 Apr 2007	Regulatory Application
17 Apr 2007	Holding(s) in Company
18 Apr 2007	EGM Circular
18 Apr 2007	Circ re. Incentive Plan
23 Apr 2007	Regulatory Approval
26 Apr 2007	Final Results
1 May 2007	Re: UBS Conference
1 May 2007	Further re Final Results
3 May 2007	Director/PDMR Shareholding
4 May 2007	Delist from NASDAQ
4 May 2007	EGM Result
4 May 2007	Director Shareholding
14 May 2007	Research Update

### 2. Documents filed at Companies House

All of the documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated. Copies of the documents filed with the Registrar of Companies can be obtained from Companies House ([www.companieshouse.gov.uk](http://www.companieshouse.gov.uk))

<u>Date of Filing</u>	<u>Brief Description of document(s) filed</u>	
07/06/2006	288a	Director appointed
27/06/2006	288a	Director appointed
11/07/2006	288b	Director resigned
11/07/2006	288b	Director resigned
11/07/2006	288b	Director resigned
11/07/2006	Res09	Resolutions
07/08/2006	AA	Annual Accounts
16/08/2006	AUD	Auditor's resignation
06/10/2006	288a	Secretary appointed
11/10/2006	288b	Secretary resigned
29/11/2006	288a	Director appointed
29/11/2006	288b	Director resigned
09/01/2007	395	Particulars of Mortgage/Charge

## Edgar Filing: SKYEPHARMA PLC - Form 6-K

09/01/2007	395	Particulars of Mortgage/Charge
11/01/2007	395	Particulars of Mortgage/Charge
12/02/2007	363	Return made up to 31/12/06
15/02/2007	395	Particulars of Mortgage/Charge
20/03/2007	RES10	Resolutions

3. Documents published or sent to Shareholders or filed with the UK Listing Authority viewing facility at:

Financial Services Authority  
The North Colonnade  
Canary Wharf  
London  
E14 5HS

<u>Date</u>	<u>Document</u>
1 Jun 2006	Annual Report and Notice of Meeting
12 Oct 2006	Interim Report
15 Jan 2007	EGM Circular and Notice of Meeting
18 Apr 2007	EGM Circular and Notice of Meeting

Copies of the above documents can be obtained from the Company Secretary at:

105 Piccadilly  
London  
W1J 7NJ

Name of contact and telephone number for queries:

John Murphy  
Company Secretary  
SkyePharma PLC  
Tel: 020 7491 1777

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**SkyePharma PLC**

By: /s/ John Murphy

Name: John Murphy  
Title: Company Secretary

Date: May 15, 2007